This phenotype has been ascribed to inflammation-driven insulin resistance in an NS animal model carrying an activating mutation of SHP2, while, in contrast, a mouse model expressing an inactivating mutation of SHP2 has increased glucose tolerance and is protected from HFD-induced insulin resistance. The gene discussed is PTPN11; the disease is Insulin resistance.